| 前收市價 | 61.75 |
| 開市 | 59.44 |
| 買盤 | 0.00 |
| 賣出價 | 0.00 |
| 拍板 | 60.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 59.44 - 71.10 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 25 |
Insider MonkeyIs Merck & Co., Inc. (MRK) the Best Cancer Stock to Buy Now?
We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cancer stocks. Global Oncology Market Overview and Drug Shortages In 2022, the global oncology market was valued at approximately $203.42 billion […]
BenzingaBacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Tuesday, Vaxcyte, Inc. (NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. VAX-31 was well tolerated and demonstrated a safety profile at all doses studied through the full six-month evaluation period, similar to Pfizer Inc's (NYSE:PFE) Prevnar 20 (PCV20). VAX-31 showed robust opsonophagocytic activ
ZacksMerck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
